Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Inclusion Criteria: * Histologically confirmed sarcoma that is recurrent or refractory to conventional treatment * Measurable disease by RECIST criteria * ECOG (Eastern Cooperative Oncology Group) performance status \< 2 (or Lansky/Karnofsky \> 60% for children) * Life expectancy greater than 3 months * Adequate organ function * absolute neutrophil count at least 1,500 * platelets at least 100,000 * bilirubin less than 1.5 x upper limit of normal * AST (aspartate aminotransferase) and ALT(alanine aminotransferase) less than 2.5 x upper limit of normal * creatinine less than 1.5 x upper limit of normal OR creatinine clearance at least 60 ml/min/1.73 m2 * fasting serum cholesterol less than 350 * fasting serum triglycerides less than 400 * PT (prothrombin) or INR (international normalized ratio) less than 1.3 x upper limit of normal * normal urinalysis * Ability to understand and sign the informed consent document Exclusion Criteria: * Prior chemotherapy or radiotherapy within 3 weeks of entering the study (6 weeks for nitrosoureas or mitomycin C) * Prior treatment with a tyrosine kinase inhibitor within 10 days of entering the study * History of pulmonary hypertension or pneumonitis * Patients may not be receiving other investigational agents * Prior therapy with rapamycin, rapamycin analogues, or tacrolimus * Uncontrolled brain metastases * History of grade 3 or 4 hypersensitivity to macrolide antibiotics * Concurrent treatment with immunosuppressive agents other than a stable (for more than 2 weeks) dose of corticosteroids * Uncontrolled intercurrent illness * Pregnancy or breast feeding * HIV-positive patients on combination antiretroviral therapy * Grade 3 or 4 proteinuria